ArticleTransplantation and cellular therapy2026
Real-World Analysis of Post-Transplant Cyclophosphamide on Allogeneic HCT Landscape.
Tara Sebastian, Tingyu Wang, Ioannis E Louloudis, Pavan Reddy, James L M Ferrara, John E Levine
Abstract readLetter
In one paragraphArticle in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Tara SebastianDivision of Hematology/Medical Oncology, The Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York.
Tingyu WangDivision of Hematology/Medical Oncology, The Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York.
Ioannis E LouloudisDivision of Hematology/Medical Oncology, The Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York.
Pavan ReddyBaylor College of Medicine, Dan Duncan Cancer Center, Houston, Texas.
James L M FerraraDivision of Hematology/Medical Oncology, The Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York.
John E LevineDivision of Hematology/Medical Oncology, The Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: john.levine@mssm.edu.
Funding
TUMOR VACCINES AND BONE MARROW TRANSPLANTATIONP01CA039542 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JOHN LEVINE · 1985 to 2026
$47.9MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MMount Sinai StARR Program - NIAIDR38AI181012 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENJAMIN K CHEN, Jaime C Chu · 2024 to 2026
$918kValidation of a novel and more accurate endpoint for GVHD clinical trialsR21HL177578 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JOHN LEVINE · 2025 to 2026
$254kNCI NIH HHS P01 CA039542NCI NIH HHS P30 CA196521NHLBI NIH HHS R21 HL177578NIAID NIH HHS R38 AI181012
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID42503349
PMCPMC13492731
What OpenQuestion holds
Textmetadata
Read underepoch 390